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ABSTRACT 
Objective: Two simple and sensitive techniques-one spectrophotometric and one titrimetric-have been developed for the determination of 3,3'-
(propane-1,3-diyl)bis(7,8-dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one) commonly known as ivabradine impurity-9 (IVA-9). 
Methods: The spectrophotometric method is based on the oxidation of drug impurity by excess cerium (IV) sulphate in acidic medium and the 
subsequent reaction of the remaining Ce(IV) with a known amount of ferrous ammonium sulphate. The resultant ferric ion is then made to react 
with thiocyanate in acid medium to form a brown coloured complex which is analyzed spectrophotometrically against the reagent blank. In the 
volumetric method, the un-reacted Ce(IV) is titrated against standard ferrous ammonium sulphate to estimate the quantity of IVA-9.  
Results: The colored complex showed an absorption maximum at 479 nm when measured spectrophotometrically. The stated methods are 
validated statistically using the International Council for Harmonization guidelines-ICH Q2(R1) for precision and accuracy. The method showed a 
linear response from 0.5 to 100µg/ml with a correlation coefficient of 0.9985. 
Conclusion: No estimation techniques have been reported to date for the determination of this molecule. The proposed techniques may be used for 
the routine quantification in its pure form and also in the presence of its parent drug molecule Ivabradine. 
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benzo[d]azepin-2-one) (IVA-9) is a pharmaceutical impurity formed 
en route the synthesis of anti-ischaemic drug ivabradine. Ivabradine is 
a cardiotonic agent used to treat suggestive chronic heart failures 
which are not managed by beta blockers. It’s efficiency in treating 
angina pectoris and myocardial ischemia, without any negative 
hemodynamic effects, has been described [1]. Estimation of ivabradine 
has been achieved in the past by high-performance liquid 
chromatography [2-4], thin layer chromatography [5-8], liquid 
chromatography with spectrometry [9-11] and spectrophotometry 
[12, 13]. The polymorphism, co-crystallization [14], crystal chemistry 
[15] and sustained release studies [16] of ivabradine were reported. X-
ray analysis and conformational studies [17] showed the chlorine salt 
of ivabradine as a horseshoe-shaped diastereomer with two 
asymmetric bicyclic moieties. The first part is made up of a seven-
membered lactam structure and the second part contains a four-
membered ring. The structure and properties of IVA-9 are expected to 
be significantly different from that of ivabradine as it is made up of two 
symmetric benzazepine units connected via aliphatic acyclic linkage 
and lacking tertiary amino nitrogen as seen in fig. 1(a) and 1(b). 
The structural and chemical properties of drug molecules and their 
intermediates play a big role in pharmacokinetics and drug action. As 
IVA-9 is an intermediate impurity of drug ivabradine, we tried to 
explore the molecule. However, the perusal of literature revealed a 
dearth of details regarding the structure and property of this molecule. 
Though the spectrophotometric estimation of ivabradine in the 
presence of its degradation products has been described by Mostafa et 
al. [18], the structural properties of the title molecule were 
unexplored. Further, no estimation techniques have been reported so 
far to determine IVA-9 in its pure form or as a pharmaceutical 
intermediate. The authors have performed similar studies in the past 
on 4-nitro 2-phenoxy aniline using 8-hydroxyquinoline which is an 
impurity associated with the drug nimesulide [19, 20]. As an extension 
study, we propose one spectrophotometric method and one 
volumetric method for the determination of IVA-9 in the pure form 
also in the presence of its parent drug molecule ivabradine. 
 
Fig. 1(a): Structure of IVA-9 
 
 
Fig. 1(b): Structure of ivabradine 
 
The proposed methods involve the oxidation of IVA-9 by a surplus 
amount of Ce(IV) and the subsequent reaction of the remaining 
Ce(IV) with a known amount of ferrous ammonium sulphate. The 
resultant ferric ion is then made to react with thiocyanate in an acid 
medium to form a brown colour complex [21].  
Reaction Scheme 
Drug+Ce(IV) → Oxidized form of drug+Ce(III) 
Excess Ce(IV)+Fe+2→ Ce(III)+Fe+3 
Fe+3+SCN-→ Complex 
Optimum reagent and reaction conditions were arrived at by fixing 
the concentration of one reagent while varying others. Ideal reagent 
concentrations and sequence of addition are listed below.  
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Different aliquots of reagent stock were mixed with 1 ml of 5 M 
hydrochloric acid and 3 ml of Ce(IV) sulpahate (400 µg/ml) and 
allowed to stand for 15 min. To this 2 ml of ferrous ammonium 
sulphate (300 µg/ml) was added and after 5 min, 1 ml of 30% 
potassium thiocyanate was added and mixed well. The solution was 
then made up using double distilled water and analyzed 
spectrophotometrically. The absorption maximum was recorded at 
479 nm against the reagent blank (fig. 2).  
The listed methods are validated statistically using ICH Q2(R1) 
guidelines[22]. The precision and accuracy of the method were 
ascertained by both intraday and interday recovery studies and 
given in table 1. 
The sensitivity of the method is apparent from various regression 
parameters such as sandell sensitivity, molar absorptivity, limit of 
detection, limit of quantification etc. and demonstrated in table 2. 
Under the listed optimum conditions, a linear response has been 
observed between absorbance and concentration of drug impurity 
over a wide range (fig. 3). 
 
Fig. 2: Absorption maximum at 479 nm 
 
Table 1: Recovery studies 
Technique Iva-9 added Intra-day assessment Inter-day assessment 
Iva-9 obtained % RE % RSD Iva-9 obtained % RE % RSD 
Spectrophotometry 
(µg/ml) 
1.0 1.02 2.00 2.58 0.98 2.00 2.85 
2.0 2.03 1.50 1.05 1.98 1.00 1.33 
3.0 3.03 1.00 0.87 2.95 1.67 1.80 
Titration 
(mg) 
2.0 2.02 1.00 0.98 1.95 2.50 2.80 
4.0 4.04 1.00 1.33 3.94 1.50 1.80 
6.0 6.03 0.50 0.55 5.92 1.33 2.20 
 
Table 2: Regression parameters 
Parameter Range 
λMax, nm 479 nm 
Beer’s Law range, µg/ml 0.5–100 mg/l 
Molar absorptivity, L mol-1 cm-1 1.86062 x105 
Limit of detection, µg/ml 0.14 
Limit of quantification, µg/ml 0.42 
Sandell sensitivity 0.0027 





Correlation Coefficient -0.99848 
*Y=a+bX, where Y is absorbance and X is concentration (µg/ml), Sa = Standard deviation of intercept and Sb = Standard deviation of the slope. 
 
 
Fig. 3: Calibartion curve 
 
For volumetric estimation, 10 ml of 50 µg/ml equivalent of stock 
solution is mixed with 1 ml of 1 M sodium acetate and 5 ml of 0.05M of 
Ce(IV) sulpahate. The contents were mixed throughly and made to stand 
for 15 min. To this 5 ml of 3 M sulphuric acid solution was added and 
titrated against 0.05 M ferrous ammonium sulphate using ferroin 
indicator. The experiment was repeated with a blank titration for 
comparison.  
The reported methods are free from cumbersome extraction steps. 
Since no estimation techniques have been reported till date, the 
authors are hopeful that the proposed methods could be used for the 
determination of IVA-9 in the pure form and in pharmaceutical 
formulations. Further, there is scope to explore the said method as a 
marker test to find the presence 3,3'-(propane-1,3-diyl)bis(7,8-
dimethoxy-1,3,4,5-tetrahydro-2H-benzo[d]azepin-2-one) as an 
impurity in the parent drug ivabradine. 
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